Technical analysis of TG Therapeutics, Inc. (TGTX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders.
Price Performance
| 1 month | +11.12% |
| 3 months | +4.94% |
| Year-to-date | +87.35% |
| 1 year | +74.31% |
| 3 years | +487.28% |
| 5 years | +78.55% |
52-Week Range
| 52-week High | $59.30 |
| 52-week Low | $26.76 |
| Avg Volume (90d) | 2.2M |
Technical Indicators
| SMA 50 | $53.51 |
| SMA 200 | $39.82 |
| Beta | 1.75 |
| 30-day Volatility (annualised) | 37.5% |
| Price vs SMA 50 | +4.4% |
| Price vs SMA 200 | +40.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $34.78 | |
| 2025-11 | $33.26 | -4.4% |
| 2025-12 | $29.81 | -10.4% |
| 2026-01 | $29.43 | -1.3% |
| 2026-02 | $30.09 | +2.2% |
| 2026-03 | $33.22 | +10.4% |
| 2026-04 | $33.78 | +1.7% |
| 2026-05 | $37.94 | +12.3% |
| 2026-06 | $54.94 | +44.8% |
| 2026-07 | $52.03 | -5.3% |
| 2026-08 | $54.30 | +4.4% |
| 2026-09 | $55.85 | +2.9% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $55.85 |
| Market Cap | $8.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 18.34 |
| Price / Book | 13.11 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 1.25 |
| Current Ratio | 4.27 |